Tunku Varadarajan, Barney Spender, Andrew Pierce, Political Correspondent, Patricia Davies, Richard Ford, Home Correspondent, Caroline Merrell, Nathan Yates and Anne Ashworth, Richard Hobson, Ivo Tennant, Robert Neild, Philip Howard, Susan Bell, A. G. Sheard, Hilary Finch, Ian Murray, Michael Binyon, Chris Bowers, Grace Bradberry and Lin Jenkins, Carl Mortished, Gillian Maxey, Simon Wilde, Kevin Eason, Michael Evans and Valerie Elliott, Geoff Brown, Robert Sheehan, Bridge Correspondent, Robert Miller, Arthur Leathley Political Correspondent, Walton of Detchant, Pat Gibson, Jill Sherman, Chief Political Correspondent, Jerey Kingston, Rupert Cox, John Hopkins, Golf Correspondent, Shirley English, Raymond Keene Chess Correspondent, Ruth Gledhill Religion Correspondent, Dave Wilson, David Lloyd, Martin Barrow, Lord Montagu, Ian Murray, Medical Correspondent, Jill Sherman Chief Political Correspondent, Michael Clark, Eve-Ann Prentice, Anatole Kaletsky, David Hands, Rodney Legg (Warden), Norman Hammond Archaeology Correspondent, Peter Barnard, Geoffrey Matthews, Richard Falconer, Manoah Esipisu, Nigel Williamson, Audrey Magee, Ireland Correspondent, Dominic Kennedy and Daniel McGrory, Paul Sexton, Gill Bowker, Adam Jones, Raymond Keene, Vaughan Freeman, John Meurig Thomas, Alan Lee, Cricket Correspondent, Paul Wilkinson and Ruth Gledhill, Alan Bradley (Chairman), Paul Wilkinson, P. H. S, Stewart Tendler and Russell Jenkins, Andrew Drummond, Bronwen Maddox, Eric Reguly, Michael Calvin, Roger Boyes, Nigel Hawkes, Science Editor, Sarah Cunningham, Oliver August, Andrew Pierce Political Correspondent, Alan Winter, David Price, John Allison, Richard Duce, Martin Waller, Deputy City Editor, Nick Szczepanik, John Lloyd, Guy Walters, Giles Whittell, Philip Webster Political Editor, Charles Lloyd, Christopher Walker, James Pringle, Chris Parker, Alan Copps, Jonathan Palmer, Susan Elkin, Matthew Parris, Richard Evans Racing Correspondent, Chris McGrath, John Shaw, Caitlin Moran, Peter Riddell, Glenn Sterling, Jean Marcus, Richard Ecans, Tony Dawe, Richard Beeston, David Sinclair, Fraser Nelson, Martin Waller, Frances Gibb and Joanna Bale, Michael Horsnell, Nigel Hawkes Science Editor, Benedict Nightingale, Robert A. Crawford, Frances Gibb Legal Correspondent, Hugh Thompson, Julian Muscat Tennis Correspondent, Richard Morrison, David Powell, Sam Kiley, Jack Bailey, David Maddock, Michael Evans, Alasdair Murray, Robert Whymant, Alan Jackson, Mark Fuller, Jan Raath, Edward Gorman Sailing Correspondent, David Hands, Rugby Correspondent, Mike Rosewell, Rowing Correspondent, Jonathan Mirsky, Christine Buckley, Industrial Correspondent, Arthur Leathley Transport Correspondent,
... Mass Baron Patten Latest wills Forthcoming marriages Kim Casali Kim Casali, Cartoonist, died after a short illness at her ...
1997 - Gale Group | TDA
Elisa Mazzoni, Maria Gerosa, Francesco Lupidi, Alfredo Corallini, Angelo Taronna, Antonio D’Agostino, Massimo Bovenzi, Giacomo Ruggeri, Ferruccio Casali, John Charles Rotondo, Giovanni Rezza, Giuseppe Barbanti‐Brodano, Mauro Tognon, Fernanda Martini,
Glioblastoma multiforme (GBM) is a rare tumor, which affects 1/100 000 individuals, but it represents 30% of central nervous system malignancies. GBM is a severe tumor responsible for 2% of all cancer-related deaths. Although characterized by genotypic and phenotypic heterogeneities, GBM invariably resists conventional chemo- and radiotherapies. Several chromosome alterations and gene mutations were detected in GBM. Simian virus 40 (SV40), a small DNA tumor virus, has been found in GBM specimens by ...
Tópico(s): Energy Harvesting in Wireless Networks
2013 - Oxford University Press | Neuro-Oncology
Bernhard Dietzschold, Milind M. Gore, Paolo Casali, Y Ueki, Charles E. Rupprecht, A L Notkins, Hilary Koprowski,
Rabies virus antigen-specific human monoclonal antibodies (MAbs) that recognized either viral glycoprotein, ribonucleoprotein, or matrix proteins were generated. Only glycoprotein-specific MAb neutralized a variety of rabies viruses and protected laboratory rodents against lethal rabies virus infection. The determinant recognized by this MAb does not appear to reside in previously defined antigenic sites of the viral glycoprotein.
Tópico(s): Virology and Viral Diseases
1990 - American Society for Microbiology | Journal of Virology
Chandrajit P. Raut, Rosalba Miceli, D. Strauß, Carol J. Swallow, Peter Hohenberger, Frits van Coevorden, Piotr Rutkowski, Marco Fiore, Dario Callegaro, Paolo G. Casali, Rick L. Haas, Andrew Hayes, Charles Honoré, Amanda J. Cannell, Jens Jakob, Milena Szacht, Mark Fairweather, Raphael E. Pollock, Sylvie Bonvalot, Alessandro Gronchi,
BACKGROUND A multi‐institutional nomogram for predicting disease‐free survival (DFS) and overall survival (OS) in patients with primary retroperitoneal sarcoma (RPS) incorporating relevant prognostic factors not included in the American Joint Committee on Cancer staging system for soft tissue sarcoma has been reported. The authors validated this nomogram with an independent, transatlantic cohort. METHODS Data from patients with RPS who were undergoing definitive resection at 1 of 6 sarcoma centers ...
Tópico(s): Vascular Tumors and Angiosarcomas
2016 - Wiley | Cancer
Suzanne George, Jean‐Yves Blay, Paolo G. Casali, Axel Le Cesne, S. E. DePrimo, Charles S. Harmon, Calvin Law, Vanessa Tassell, Charles M. Baum, George D. Demetri,
10554 Background: SU is an oral multitargeted tyrosine kinase inhibitor of KIT, PDGFRs, VEGFRs, FLT3, CSF-1R and RET, approved multinationally for the treatment of advanced imatinib (IM)-resistant/intolerant GIST on an intermittent dosing schedule comprising 4 wk on 50 mg/d followed by 2 wk off treatment. The safety and efficacy of SU 37.5 mg CDD in pts with GIST after IM failure were evaluated in this phase II study. Methods: In this open-label, multicenter trial, pts were randomized either to morning ( ...
Tópico(s): Platelet Disorders and Treatments
2008 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Elisa Mazzoni, Mariantonietta Di Stefano, J R Fiore, Federica Destro, Marco Manfrini, John Charles Rotondo, Maria Vittoria Casali, Fortunato Vesce, Pantaleo Greco, Gennaro Scutiero, Fernanda Martini, Mauro Tognon,
Simian virus 40 (SV40) large T antigen ( LT ) coding sequences were revealed in different human samples, whereas SV40 antibodies (Ab) were detected in human sera of cancer patients and healthy individuals, although with a lower prevalence. Previous studies carried out by the neutralization assay gave a SV40 seroprevalence, in the general population, up to 8%, although higher rates, 12%, were detected in kidney transplant children, in a group of HIV-positive patients, and in healthy females. In this study, ...
Tópico(s): Full-Duplex Wireless Communications
2017 - Frontiers Media | Frontiers in Immunology
Dario Callegaro, Rosalba Miceli, Sylvie Bonvalot, Peter C. Ferguson, D. Strauß, Antonin Lévy, Anthony M. Griffin, Andrew Hayes, Silvia Stacchiotti, C. Le Péchoux, Myles J. Smith, Marco Fiore, Angelo Paolo Dei Tos, Henry Smith, Charles Catton, Paolo G. Casali, Jay S. Wunder, Alessandro Gronchi,
The role of radiotherapy (RTx) and chemotherapy (CTx) in primary extremity soft tissue sarcoma (eSTS) patients is not precisely defined.All consecutive primary eSTS patients treated within three European and one North American reference centres in a 20-year time span were included. The tendency to perform chemotherapy/radiotherapy (CTx/RTx) was explored using multivariable binary logistic models. Five and 10-year overall survival (OS) and crude cumulative incidence (CCI) of local recurrence (LR) and distant ...
Tópico(s): Bone Tumor Diagnosis and Treatments
2018 - Elsevier BV | European Journal of Cancer
Suzanne George, Jean‐Yves Blay, Paolo G. Casali, Axel Le Cesne, Patricia Stephenson, Samuel E. DePrimo, Charles S. Harmon, Calvin Law, Jeffrey A. Morgan, Isabelle Ray‐Coquard, Vanessa Tassell, D. P. Cohen, George D. Demetri,
Aims To assess the antitumour activity, safety, pharmacokinetics and pharmacodynamics of continuous daily sunitinib dosing in patients with imatinib-resistant/intolerant gastrointestinal stromal tumour (GIST) and to assess morning dosing versus evening dosing. Patients and methods In this open-label phase II study, patients were randomised to receive morning or evening dosing of sunitinib 37.5 mg/day. The primary end-point was clinical benefit rate (CBR; percent complete responses + partial responses [ ...
Tópico(s): Platelet Disorders and Treatments
2009 - Elsevier BV | European Journal of Cancer
G. D. Demetri, Xiaoyan Huang, Christopher R. Garrett, Patrick Schöffski, Martin E. Blackstein, Manisha H. Shah, Jaco J. Verweij, Vanessa Tassell, Charles M. Baum, Paolo G. Casali,
10524 Background: SU is an oral multitargeted tyrosine kinase inhibitor of KIT, PDGFRs, VEGFRs, FLT3, CSF-1R and RET, approved multinationally for treatment of advanced GIST after IM failure. Interim analysis of a double-blind, PL-controlled phase III trial in this pt population showed a significant difference in OS between pts randomized to SU (50 mg/d administered in 6-wk cycles of 4 wk on treatment, 2 wk off; N=207) or PL (N=105) favoring SU (HR 0.49; P=0.007), without medians having been reached. ...
Tópico(s): Lymphoma Diagnosis and Treatment
2008 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett, Martin E. Blackstein, Manisha H. Shah, Jaap Verweij, Grant A. McArthur, Ian Judson, Michael C. Heinrich, Jeffrey A. Morgan, Jayesh Desai, Christopher D.�M. Fletcher, Suzanne George, Carlo L. Bello, Xin Huang, Charles M. Baum, Paolo G. Casali,
Background No effective therapeutic options for patients with unresectable imatinib-resistant gastrointestinal stromal tumour are available. We did a randomised, double-blind, placebo-controlled, multicentre, international trial to assess tolerability and anticancer efficacy of sunitinib, a multitargeted tyrosine kinase inhibitor, in patients with advanced gastrointestinal stromal tumour who were resistant to or intolerant of previous treatment with imatinib. Methods Blinded sunitinib or placebo ...
Tópico(s): Gastric Cancer Management and Outcomes
2006 - Elsevier BV | The Lancet
G. D. Demetri, A.T. van Oosterom, Martin E. Blackstein, Chris R. Garrett, Manisha H. Shah, Michael C. Heinrich, Grant A. McArthur, Ian Judson, Charles M. Baum, Paolo G. Casali,
4000 Background: Inhibition of aberrant kinase signalling through the KIT or PDGFRα receptors with imatinib therapy has improved survival for pts with metastatic GIST, but over time, clonal evolution leads to imatinib-resistant disease. Imatinib resistance may be due to several mechanisms, including complex patterns of secondary kinase mutations. SU11248, an oral multitargeted tyrosine kinase inhibitor, has antiangiogenic and antitumor activity due to inhibition of signalling by VEGFR, PDGFRα and ...
Tópico(s): Platelet Disorders and Treatments
2005 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Mauro Tognon, Mario Luppi, Alfredo Corallini, Angelo Taronna, Patrizia Barozzi, John Charles Rotondo, Manola Comar, Maria Vittoria Casali, Massimo Bovenzi, Antonio D’Agostino, Fabrizio Vinante, Antonella Rigo, Isacco Ferrarini, Giuseppe Barbanti‐Brodano, Fernanda Martini, Elisa Mazzoni,
BACKGROUND Non‐Hodgkin lymphoma (NHL), the most common cancer of the lymphatic system, is of unknown etiology. The identification of etiologic factors in the onset of NHL is a key event that could facilitate the prevention and cure of this malignancy. Simian virus 40 (SV40) has been considered an oncogenic agent in the onset/progression of NHL. METHODS In this study, an indirect enzyme‐linked immunosorbent assay with 2 synthetic peptides that mimic SV40 antigens of viral capsid proteins 1 to 3 was ...
Tópico(s): Full-Duplex Wireless Communications
2015 - Wiley | Cancer
Elliott H. Berger, John R. Franks, Alberto Behar, John G. Casali, Christine Dixon-Ernst, Ronald W. Kieper, Carol J. Merry, Ben T. Mozo, Charles W. Nixon, Doug Ohlin, Julia Doswell Royster, Larry H. Royster,
The mandate of ASA Working Group S12/WG11 has been to develop "laboratory and/or field procedure(s) that yield useful estimates of field performance" of hearing protection devices (HPDs). A real-ear attenuation at threshold procedure was selected, devised, tested via an interlaboratory study, and incorporated into a draft standard that was approved in 1997 [J. D. Royster et at., "Development of a new standard laboratory protocol for estimating the field attenuation of hearing protection devices. Part ...
Tópico(s): Structural Health Monitoring Techniques
1998 - Acoustical Society of America | The Journal of the Acoustical Society of America
Suzanne George, Jean‐Yves Blay, Paolo G. Casali, Axel Le Cesne, Jeffrey A. Morgan, J. Pokela, Mikayla Quigley, Vanessa Tassell, Charles M. Baum, George D. Demetri,
10015 Background: SU, an oral multitargeted tyrosine kinase inhibitor of KIT, PDGFRs, VEGFRs, RET and FLT3, is approved multinationally for the treatment of imatinib (IM)-resistant or -intolerant GIST. SU 50 mg/d on a 4/2 schedule (6-wk cycles: 4 wks on treatment, 2 wks off) has demonstrated efficacy and acceptable tolerability in pts with advanced IM-resistant GIST. The current study assesses the efficacy and safety of CDD of SU in this pt population. Methods: In this multicenter phase (ph) II trial, ...
Tópico(s): Chronic Myeloid Leukemia Treatments
2007 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Suzanne George, Paolo G. Casali, Jean‐Yves Blay, Axel Le Cesne, Andreas Tyler, Mikayla Quigley, Vanessa Tassell, Charles M. Baum, George D. Demetri,
9532 Background: Sunitinib malate (SU11248) is an oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities due to inhibition of KIT, VEGFRs, PDGFRs, RET, and FLT3. In previous phase I/II and III trials in pts with imatinib-resistant GIST, sunitinib demonstrated efficacy and favorable clinical tolerability when administered in 6-week treatment cycles consisting of 4 weeks sunitinib (50 mg QD), followed by 2 weeks off treatment. The current study examined continuous ...
Tópico(s): Lung Cancer Treatments and Mutations
2006 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Matthias Vanmaercke, Panos Panagos, Tom Vanwalleghem, Antonio Hayas, Saskia Foerster, Pasquale Borrelli, Mauro Rossi, Dino Torri, Javier Casalí, L. Borselli, Olga Vigiak, Michael Maerker, Nigussie Haregeweyn, Sofie De Geeter, Wojciech Zgłobicki, Charles Bielders, Artemi Cerdà, Christian Conoscenti, Tomás de Figueiredo, Bob Evans, V. N. Golosov, Ion Ioniţă, Christos Karydas, Ádám Kertész, Josef Krása, Caroline Le Bouteiller, Mariá Rãdoane, Ratko Ristić, Svetla Rousseva, Miloš Stankoviansky, Jannes Stolte, Christian Stolz, Rebecca Bartley, Scott Wilkinson, Ben Jarihani, Jean Poesen,
Soil erosion is generally recognized as the dominant process of land degradation. The formation and expansion of gullies is often a highly significant process of soil erosion. However, our ability to assess and simulate gully erosion and its impacts remains very limited. This is especially so at regional to continental scales. As a result, gullying is often overlooked in policies and land and catchment management strategies. Nevertheless, significant progress has been made over the past decades. ...
Tópico(s): Aeolian processes and effects
2021 - Elsevier BV | Earth-Science Reviews
J. R. Broadwater, Robert L. Bryant, R Petrino, Charles D. Mabry, Kent C. Westbrook, Robert E. Casali,
Hidradenitis suppurativa remains a poorly understood disease involving the apocrine sweat glands. Management of 23 patients with the advanced form of the disease has been reviewed. Local therapy and incision and drainage all have an unacceptable rate of recurrence. From our experience, we recommend wide and deep excision of the area involved combined with individualized closure.
Tópico(s): Chemotherapy-related skin toxicity
1982 - Elsevier BV | The American Journal of Surgery
George D. Demetri, Robert S. Benjamin, Charles D. Blanke, Jean‐Yves Blay, Paolo G. Casali, Haesun Choi, Christopher L. Corless, Maria Dębiec‐Rychter, Ronald P. DeMatteo, David S. Ettinger, George A. Fisher, Christopher D.�M. Fletcher, Alessandro Gronchi, Peter Hohenberger, Miranda Hughes, Heikki Joensuu, Ian Judson, Axel Le Cesne, Robert G. Maki, Michael A. Morse, Alberto S. Pappo, Peter W. T. Pisters, Chandrajit P. Raut, Peter Reichardt, Douglas S. Tyler, Annick D. Van den Abbeele, Margaret von Mehren, Jeffrey D. Wayne, John Zalcberg,
The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice rapidly changed after the introduction of effective molecularly targeted therapy (such as imatinib and sunitinib) for GIST. Because of these changes, NCCN organized a multidisciplinary panel composed of experts in the fields of medical oncology, molecular diagnostics, pathology, radiation oncology, and surgery to discuss the optimal approach ...
Tópico(s): Gastric Cancer Management and Outcomes
2007 - National Comprehensive Cancer | Journal of the National Comprehensive Cancer Network
Michio Hirano, Ramón Martí, Carlo Casali, S. Tadesse, TS Uldrick, Brian Fine, Diana M. Escolar, Maria Lucia Valentino, Ichizo Nishino, Charles Hesdorffer, Joseph E. Schwartz, R. Hawks, Daniel Martone, Mitchell S. Cairo, S. DiMauro, Marta Stanzani, James H. Garvin, David G. Savage,
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a multisystemic autosomal recessive disease due to primary thymidine phosphorylase (TP) deficiency. To restore TP activity, we performed reduced intensity allogeneic stem cell transplantations (alloSCTs) in two patients. In the first, alloSCT failed to engraft, but the second achieved mixed donor chimerism, which partially restored buffy coat TP activity and lowered plasma nucleosides. Thus, alloSCT can correct biochemical abnormalities ...
Tópico(s): Metabolism and Genetic Disorders
2006 - Lippincott Williams & Wilkins | Neurology
Chiara Colombo, Rosalba Miceli, C. Le Péchoux, Elena Palassini, Charles Honoré, Silvia Stacchiotti, Olivier Mir, Paolo G. Casali, Julien Dômont, Marco Fiore, Axel Le Cesne, Alessandro Gronchi, Sylvie Bonvalot,
Background To analyse the natural history of extra-abdominal wall desmoid-type fibromatosis (DF) and compare outcome in patients who underwent initial surgery with those who did not. Patients and methods All consecutive patients affected by primary sporadic extra-abdominal wall DF observed between January 1992 and December 2012 were included. Patients were divided into surgical (SG) or non-surgical groups (NSG) according to initial treatment. Relapse free survival was calculated for SG, and crude cumulative ...
Tópico(s): Sarcoma Diagnosis and Treatment
2014 - Elsevier BV | European Journal of Cancer
Paolo G. Casali, Christopher R. Garrett, Martin E. Blackstein, Manisha H. Shah, Jaap Verweij, Grant A. McArthur, Ian Judson, James Li, Charles M. Baum, George D. Demetri,
9513 Background: Sunitinib malate (previously known as SU11248) is an oral multitargeted tyrosine kinase inhibitor with both antitumor and antiangiogenic effects due to blockade of KIT, PDGFRs, VEGFRs, FLT3, and RET. Initial results from this phase III trial showed sunitinib was associated with significantly longer TTP than placebo in IM-resistant GIST pts. Methods: This double-blind, placebo-controlled, phase III trial compared sunitinib 50 mg/day (N=207) to placebo (N=105) in IM-resistant or -intolerant ...
Tópico(s): Chronic Myeloid Leukemia Treatments
2006 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
George D. Demetri, Christopher R. Garrett, Patrick Schöffski, Manisha H. Shah, Jaap Verweij, Serge Leyvraz, Herbert I. Hurwitz, Antonio López‐Pousa, Axel Le Cesne, David S. Goldstein, Luis Paz‐Ares, Jean‐Yves Blay, Grant A. McArthur, Qiang Xu, Xin Huang, Charles S. Harmon, Vanessa Tassell, Darrel P. Cohen, Paolo G. Casali,
To analyze final long-term survival and clinical outcomes from the randomized phase III study of sunitinib in gastrointestinal stromal tumor patients after imatinib failure; to assess correlative angiogenesis biomarkers with patient outcomes.Blinded sunitinib or placebo was given daily on a 4-week-on/2-week-off treatment schedule. Placebo-assigned patients could cross over to sunitinib at disease progression/study unblinding. Overall survival (OS) was analyzed using conventional statistical methods ...
Tópico(s): Sarcoma Diagnosis and Treatment
2012 - American Association for Cancer Research | Clinical Cancer Research
Julia Doswell Royster, Elliott H. Berger, Carol J. Merry, Charles W. Nixon, John R. Franks, Alberto Behar, John G. Casali, Christine Dixon-Ernst, Ronald W. Kieper, Ben T. Mozo, Doug Ohlin, Larry H. Royster,
This paper describes research conducted by Working Group 11 of Accredited Standards Committee S12, Noise, to develop procedures to estimate the field performance of hearing protection devices (HPDs). Current standardized test methods overestimate the attenuation achieved by workers in everyday use on the job. The goal was to approximate the amount of attenuation that can be achieved by noise-exposed populations in well-managed real-world hearing conservation programs, while maintaining acceptable ...
Tópico(s): Hearing Loss and Rehabilitation
1996 - Acoustical Society of America | The Journal of the Acoustical Society of America
... Casali and Fabio Stok) 6b. Postclassical commentary Sergio Casali and Fabio Stok 7. Virgil in English translation Colin Burrow 8. Virgils from Dante to Milton Colin Burrow 9. Virgil in art L. B. T. Houghton Part II. Forms: 10. Green politics: the Eclogues Charles Martindale 11. Virgilian didaxis: value and meaning in ...
Tópico(s): Literary and Philosophical Studies
1998 - Association of College and Research Libraries | Choice Reviews Online
Charles A. Nelson, Robert E. Casali, Manford D. Morris,
The serum lipoproteins of Macaca fasicularis monkeys subjected to portacaval shunts were compared to those of sham-operated on both chow and cholesterol-fat diets. On either diet, only the HDL (high-density lipoprotein) cholesterol levels were found to be significantly different between sham-operated and shunted monkeys. The HDL cholesterol of the shunted were a third lower on the chow diet (P < .025) and 50% lower on the cholesterol diet (P < .005) by both direct isolation of the VLDL, LDL, and HDL lipoprotein ...
Tópico(s): Cardiovascular Disease and Adiposity
1979 - Academic Press | Biochemical Medicine
Alessandro Gronchi, Rosalba Miceli, Marc‐Antoine Allard, Dario Callegaro, C. Le Péchoux, Marco Fiore, Charles Honoré, Roberta Sanfilippo, Sara Coppola, Silvia Stacchiotti, Philippe Terrier, Paolo G. Casali, Axel Le Cesne, Luigi Mariani, Chiara Colombo, Sylvie Bonvalot,
Tópico(s): Vascular Tumors and Angiosarcomas
2014 - Springer Science+Business Media | Annals of Surgical Oncology
Hesham Abdelhady, Marwa Abdelrazik, Zakee Abdi, D. Abdo, Amina Abdulle, Lynn Abel, Shrefee Abouzeenni, Gail Abrahamson, Yousuf Abusamra, Lisa C. Adams, Olumide Adebambo, Debo Ademokun, Neill K. J. Adhikari, Dominic Affron, Anu Aggarwal, Ronan Agno, Humayun Ahmad, Norfaizan Ahmad, Sophia Ahmed, Kate Ainscough, James Ainsworth, Giulia Airoldi, Lindianne Aitken, Francis Ajeneye, Naim Akhtar, Olajide Akinwumiju, Manaf Al-Bayati, Martin Albert, Meera Alderman, Ana Alegria, Brian Alexander, Peter Alexander, Jordan Alfonso, Hoodo Ali, Sabira Ali, Allameddine Allameddine, Sheila Allan, Isabelle Allard, Barbara Allen, B. Allen, Jess Allen, Laura K. Allen, Louise Allen, Suzanne Allibone, Richard Ambrosino, Kenneth Amenyah, Mariam Ammoun, Rekha Anand, Sai Priya Anand, Kristen Andersen, Corinne Anderson, Kevin L. Anderson, Thomas Anderson, Mark Andreae, Susan Andrews, Gregory Andrikopoulos, Aisha Anjum, Matthew Anstey, Micheline Antar, David Antcliffe, Alpha Anthony, Pierre Antoine, Vikram Anumakonda, George Apostolides, Latha Aravindan, Gill Arbane, Emily Arbon, Simon Archer, Noah Aref, Ana-Marie Arias, Chantal Armali, Joel Armer-Ducker, Michelle Armstrong, Sylvia Armstrong‐Fisher, John Arnold, Sarah Arnott, Andrea Arroyo, Valérie Arsenault, Diptesh Aryal, Adeeba Asghar, Glen Ashby, Deborah Asher, Ben Ashford, Suhail Ashgar, Murtaza Asif Ali, Angelique Aspinwall, Abigail Asquith, T Atallah, Richard Athay-Hunt, Udara Attanayaka, Rita Atugonza, M Aubé, Marie‐Christine Auclair, Karen Austin, Pauline Austin, Sidra Awan, Gina Bacon, Harleen Badhesha, Kavitha Bagavathy, Dawn Baglole, Clariza Bagnas, Catherine Bagot, Sean M. Bagshaw, Nadia Baig, Stephen J. Bailey, J. Kenneth Baillie, William Bain, Sanchia Baines, Aimi Baird, Charles Baker, Evelyn Baker, Penny Bakhtiari, Dhanalakshmi Bakthavatsalam, Morteza Balaie, Gagan Bali, Sonya Balkee, Amy Ballinger, Amy Bamford, Peter Bamford, Millie Banerjee, Lauren B. Banks, Jonathan Bannard‐Smith, Nancy Banning, Bharat Bansal, Robert Banthorpe, Ian J. Barbash, Alex Barber, Russell Barber, Miriam Barbosa, Mercedes Barillas, Ryan Bariola, Gareth J. Barker, Nicky Barnes, Matthew Barnett, N. Barnett, Rebecca M. Baron, Robert D. Bart, Jazz Bartholomew, Shauna Bartley, Dávid Barton, Jan Barwell, Archana Bashyal, Kim Basile, Frances Bass, Christopher Bassford, Pavinder Bassi, Betsy Bassis, Ian J. Bateman, Michelle Bates, Samantha Bates, Donna Batty, Kris Bauchmüller, Peter Baughan, Lydia Baxter, Charlotte Baylem, Lee Bayliss, Madeleine Bayne, Eileen Bays, Renée Bazin, Gregory Beard, Kirk Beard, Richard Beasley, Lynette Beaudin, Julie Beaudoin, Guillaume Beaudoin-Bussières, Seonaid Beddows, Caroline Bedford, Deborah Beer, Salma Begum, Jasmine Beharry, Xiao Bei Zhao, Nathalie Belec, Gillian Bell, Glenda Bell, Joshua Bell, David Bellemare, Fatna Benettaib, Ann Beninato, Mehdi Benlarbi, Alexander Bennett, Christopher Bennett, Carrie Bennett-Mills, Andrea Benoit, J G Benstead, Dionne Bentley, Lauren Berg, Colin Bergin, Claudia Berscheid, Janis Best-Lane, Emily Bevan, Jeremy Bewley, Ashley Beyerl, Sanjay Bhagani, Khushpreet Bhandal, Simon C. Biddie, Jennifer Biemans, Kelly Bignell, Shailesh Bihari, Maude Bilodeau, Carron Bilton, Martin Binney, Alexandra Binnie, Julian Bion, Catherine Birch, Janine Birch, K Birchall, Isobel Birkinshaw, Raquel Bisa, Ethel Black, Bethany Blackledge, Stuart Blackmore, Annette Blackwell, Loraine Blackwood, Yvonne Bland, Mary Blanton, J W Blaxland, Donna Blofield, Margie Blom, Jasmin Board, Aneta Bociek, Sherin Bodh, Virginie Boisclair, Sam Bolton, Wayne Bolton, Hayley Bond, Stephen Bonner, Wendy Bonnert, Leigh Boorman, Catherine Booth, Bárbara Borgatta, Cameron Borhani, Naomi Borkent, Rachel Borrell, Zöe Borrill, Mamu Boshir, Brandon Bouchard, Marie-Claude Boulanger, Dounia Boumahni, Catherine Bourassa, Michelle Bourne, Richard S Bourne, D. Le-Thi Huong Boutin, Marianne Boutin, Darren Bowen, James D. Bowen, Helen Bowler, Geoff Bowyer, Carmel Boyd, Craig Boyd, Maxine Boyd, Lucie Boyer, Rebecca Boyles, Gordana Bozovic, David Brack, Charlotte Brackstone, Rob Bradburn, Barry Bradley, Paul Bradley, Sarah Bradshaw, Jane Brailsford, Susan R. Brailsford, Emily Brant, Angela Brazier, Pamela Bremmer, Morwenna Brend, Val Brennan, Stephen J. Brett, Chris Brewer, Kathy Brickell, M. Briggs, Christopher E. Brightling, Nicole Brillinger, Lutece Brimfield, Stéphanie Brisson, Terri Brittin, Laurent Brochard, Andrew Broderick, David Broggio, Farooq Brohi, Ceri Brookes, Nicole Brooks, Randy Broom, Marie Browett, Chloë Brown, Elizabeth R. Brown, Louise Brown, Mark J. Brown, Rachel Brown, Wayne Brown, Marie-Eve Brulotte, Emilie Brunet, Nigel J. Brunskill, Kayla Bryan-Morris, Julie Buchan, Alexis Buchanan, Kathleen Buckmire,
Importance The evidence for benefit of convalescent plasma for critically ill patients with COVID-19 is inconclusive. Objective To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19. Design, Setting, and Participants The ongoing Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) enrolled and randomized 4763 adults with suspected or confirmed COVID-19 between March 9, 2020, and January 18, 2021, within ...
American Medical Association
Dario Callegaro, Rosalba Miceli, Sylvie Bonvalot, Peter C. Ferguson, D. Strauß, Veroniek M. van Praag, Antonin Lévy, Anthony M. Griffin, Andrew J. Hayes, Silvia Stacchiotti, C. Le Péchoux, Myles Smith, Marco Fiore, Angelo Paolo Dei Tos, Henry Smith, Charles Catton, Joanna Szkandera, Andreas Leithner, Michiel A. J. van de Sande, Paolo G. Casali, Jay S. Wunder, Alessandro Gronchi,
Prognostic nomograms for patients with extremity soft tissue sarcoma (eSTS) typically predict survival or the occurrence of local recurrence or distant metastasis at time of surgery. Our aim was to develop and externally validate a dynamic prognostic nomogram for overall survival in eSTS survivors for use during follow-up.All primary eSTS patients operated with curative intent between 1994 and 2013 at three European and one Canadian sarcoma centers formed the development cohort. Patients with Fédération ...
Tópico(s): Bone Tumor Diagnosis and Treatments
2019 - Elsevier BV | EClinicalMedicine
N Télerman-Toppet, M. Wittek, Michèle Bacq, P Dajez, Christian Coërs, A Fassotte, Charles K. Jablecki, Ann Benton, C Scoppetta, Carlo Casali, Mauro Piantelli, Angela Vincent, John Newsom–Davis, Alfred Stracher,
BENIGN MONOCLONAL GAMMOPATHY AND RELAPSING POLYMYOSITISBenign monoclonal gammop athy (BMG) has been re portée! in association with numerous autoimmune disor ders," including myasthenia gravis,^'"' " but so far similar findings were never mentioned in polymyositis, to our knowledge.We illustrate coexisting polymyositis and BMG in the following case report.This woman, born in 1938, had an unremarkable history, with the exception of an appendicectomy and a primary tuberculous infection during childhood. ...
Tópico(s): Nerve Injury and Rehabilitation
1982 - Wiley | Muscle & Nerve
Produção Nacional
Revisado por pares
Charles Anacleto, Andréia Machado Leopoldino, Bernard Rossi, Fernando Augusto Soares, Ademar Lopes, José Cláudio Casali da Rocha, Otávia L. Caballero, Anamaria A. Camargo, Andrew J.G. Simpson, Sérgio D.J. Pena,
It has been proposed that human colorectal tumors can be classified into two groups: one in which methylation is rare, and another with methylation of several loci associated with a "CpG island methylated phenotype (CIMP)," characterized by preferential proximal location in the colon, but otherwise poorly defined. There is considerable overlap between this putative methylator phenotype and the well-known mutator phenotype associated with microsatellite instability (MSI). We have examined hypermethylation ...
Tópico(s): Epigenetics and DNA Methylation
2005 - Elsevier BV | Neoplasia